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Short Paper 
Canine distemper virus ISCOMs induce 
protection in harbour seals (Phoca 
vitulina) against phocid distemper 
but still allow subsequent infection 
with phocid distemper virus-1 
I.K.G. Visser**, E.J. Vedder*, M.W.G. van de Bildt**, C. Orvell J;, T. Barrett § 
and A.D.M.E. Osterhaus *~'~ 
A candidate canine distemper virus (CD V) ISCOM vaccine has been shown to be effective 
in protectin9 harbour seals (Phoca vitulina )from phocid distemper in 1988. However, of 
the 35 harbour seals receivin9 this vaccine upon admission to a seal rehabilitation and 
research centre (Pieterburen, The Netherlands) in 1989, six developed mild inflammatory 
symptoms of the respiratory tract. Phocid distemper virus-1 ( PDV-1) could be isolated 
from three of these animals. This indicates that the vaccine affords protection from phocid 
distemper, but may still allow PDV-1 infection of the respiratory tract. Contacts with 
non-vaccinated seals should then be prevented until no more virus is excreted. It is speculated 
that this PDV-1 infection of the respiratory tract in CDV-ISCOM vaccinated seals is 
followed by a lifelon9 immunity. 
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During recent disease outbreaks among seals in North 
West Europe and Siberia in which many thousands of 
harbour seals (Phoca vitulina) and Baikal seals (Phoca 
sibirica) died with symptoms similar to those observed 
in canine distemper, two different morbilliviruses - 
phocid distemper virus-1 (PDV-1) and phocid distemper 
virus-2 (PDV-2), respectively - were shown to be the 
primary cause of the outbreaks 1 3. The viruses were 
isolated and subsequently characterized on the basis of 
their biological, morphological, physical, protein chemical 
and antigenic properties. PDV-1 proved to be a newly 
recognized member of the genus Morbillivirus, whereas 
PDV-2 was quite similar if not identical to canine 
distemper virus (CDV) 3 
In spite of the antigenic differences between PDV-1 
and CDV, it was shown in a vaccination-challenge 
*Seal Rehabilitation and Research Centre, Hoofdstraat 94a, 
9968 AG Pieterburen, The Netherlands. t Laboratory of 
Immunobiology, National Institute of Public Health and 
Environmental Protection, PO Box 1, 3720 BA Bilthoven, The 
Netherlands. ;tState Bacteriological Laboratory, Department 
of Virology, Karolinska Institute, S-105-21 Stockholm, Sweden. 
§Institute for Animal Health, Pirbright Laboratory, Ash Road, 
Pirbright, Woking GU24 0NF, UK. ~°Division of Virology, 
Department of Infectious Diseases and Immunology, Veter- 
inary Faculty, State University of Utrecht, Yalelaan 1, 3508 
TD Utrecht, The Netherlands. ¶To whom correspondence 
should be addressed. (Received 22 July 1991; revised 13 
November 1991; accepted 28 November 1991) 
experiment that harbour seals could be protected from 
phocid distemper by vaccination with a candidate subunit 
ISCOM vaccine, based on CDV 4'5. In this experiment 
the sham vaccinated animals developed signs of distemper, 
including fever, respiratory distress, weight loss and 
nervous symptoms and died following challenge with 
PDV-I. 
Preventive vaccination with the CDV-ISCOM prepar- 
ation was then routinely implemented in several captive 
seal groups including animals in the Seal Rehabilitation 
and Research Centre (SRRC) in Pieterburen (The 
Netherlands). Upon arrival at the SRRC all animals were 
subjected to a three dose CDV-ISCOM vaccination 
protocol 5. In the 4 months before this preventive 
vaccination was implemented, more than 90% of all the 
seals admitted to the SRRC had died from phocid 
distemper. It was shown that virtually all animals which 
were CDV-seronegative at arrival had developed morbilli- 
virus-specific virus neutralizing (VN) antibody titres after 
completion of the vaccination procedure. They all 
remained free from clinical signs of phocid distemper, 
indicating that the vaccination had been successful 5.
Survival rates of animals that showed serological 
evidence of PDV-1 infection upon admission, did not 
exceed 30% after using the same vaccination schedule, 
indicating that postexposure vaccination was far less 
effective 5.
In 1989, the year following the massive phocid 
distemper epidemic in North West Europe, 35 harbour 
seals were admitted to the SRRC. Each animal was 
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Table 1 Reactivity of monoclonal antibodies (mAbs) raised against canine distemper virus (CDV, Convac strain =) and phocid distemper virus 
(PDV[-1], reference strain =) with Vero cell lysates infected with PDV isolated from seals nos 89-21, 89-30 and 89-34 as tested in an indirect ELISA' 
Virus strain/ isolate b 
mAb Raised" CDV PDV-1 PDV PDV PDV 
no. against (Convac) ref. strain no. 89-21 no. 89-30 no. 89-34 
3.564 CDV NP + . . . .  
3.662 CDV NP1 + . . . .  
3.721 CDV NP1 + - - - 
3.755 CDV NP + + + + + 
3.805 CDV NP2 + + + + + 
3.851 CDV NP + + + + + 
3.958 CDV NP3 + + + + + 
3.991 CDV NP4 + . . . .  
4.100 CDV NP5 + + + + + 
4.271 CDV NP + + + + + 
1.064C5 PDV NP1 - + + + + 
1.069G2 PDV NP2 - + + + + 
1.071E2 PDV NP1 - + + + + 
1.295F5 PDV NP + + - + - 
3.568 CDV P2 + + + + + 
3.630 CDV P + . . . .  
3.695 CDV P3 + . . . .  
3.698 CDV P1 + + NT NT NT 
3.768 CDV P + + - + - 
3.780 CDV P4 + + - + - 
3.788 CDV P + + + + + 
4.051 CDV P5 + . . . .  
4.088 CDV P6 + + - + - 
4.149 CDV P1 + + + + + 
4.415 CDV P1 + + + + + 
4.174 CDV P1 + + + + + 
1.347 CDV H1 + + + + + 
2.267 CDV H2 + . . . .  
3.734 CDV H3 + . . . .  
3.775 CDV H4 + . . . .  
3.900 CDV H3 + . . . .  
4.043 CDV H5 + + + + + 
4.074 CDV H5 + + + + + 
4.275 CDV H6 + . . . .  
4.941 CDV H7 + . . . .  
1.062G5 PDV H1 - + + + + 
1.063C3 PDV H1 - + + + + 
1.063E9 PDV H1 - + + + + 
1.067E5 PDV H2 - + + + + 
1.068F2 PDV H3 - + + + + 
1.069D9 PDV H1 + + + + + 
1.070B5 PDV H4 - + + + + 
1.071E5 PDV H1 - + + + + 
1.072C4 PDV H4 - + + + + 
1.085C4 PDV H5 - + + + . + 
1.122D11 PDV H6 + + + + + 
3.551 CDV F2 + + + + + 
3.564 CDV F2 + + + + + 
3.633 CDV F1 + + + + + 
3.697 CDV F2 + + + + + 
4.068 CDV F2 + + + + + 
4.985 CDV F3 + . . . .  
5.086 CDV F1 + + + + + 
5.148 CDV F3 + + + + + 
1.062E2 PDV F1 + + + + + 
1.067D2 PDV F2 + + + + + 
1.068B2 PDV F1 + + + + + 
1.062G PDV F3 + + + + + 
"NP1-5, nucleoprotein sites 1-5; P1-6, polymerase protein sites 1-6; H1-7, haemagglutinin protein sites 1-7; F1-3; fusion protein sites 1-3. 
~+ Reactivity in indirect ELISA; - no reactivity in ELISA; NT, not tested 
routinely checked for the presence of morbillivirus- 
specific antibodies upon arrival. Subsequently he animals 
were kept in quarantine for at least 3 weeks and both 
the seronegative (n= 20) and the seropositive (n = 15) 
seals were vaccinated thrice with the CDV-ISCOM 
preparation 5. Four of the seronegative and 13 of the 
seropositive seals were pups born in 1989. After the 
quarantine period and completion of the vaccination 
schedule, five of these pups, one (no. 89-27) which was 
originally seropositive and four which were originally 
seronegative (nos 89-21, 89-28, 89-30, 89-33), were 
gathered in one basin. Seven to thirteen weeks after 
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admission they almost simultaneously developed mild 
respiratory symptoms, including a paroxysmal cough, 
serous nasal discharge and a conjunctivitis that persisted 
for more than 2 weeks. This occurred 5-8 weeks after 
completion of the three-dose vaccination procedure 
(Figure I ), which was about 2 weeks after the introduction 
of a sixth seal pup (no. 89-34) into this group of five. 
This animal, which had also received the standard 
treatment described above, had been seropositive upon 
admission, had shown mild respiratory symptoms from 
the second week onward, but in spite of this was 
introduced into the group of five. 
Standard virus isolation procedures performed with 
swabs taken from the nose and pharnyx of these six 
affected and of five non-affected seal pups (nos 89-26, 
89-29, 89-35, 89-37 and 89-44) kept in another basin were 
carried out in primary seal kidney cell (SeKC) cultures 
with subsequent passaging in Vero cells as previously 
described 3. The swabs were taken between 3and 9 days 
after the first appearance of clinical signs in the five 
affected seal pups. Virus infection was demonstrated in 
the Veto cells inoculated with supernatants from SeKC 
cultures inoculated with swab materials taken from seal 
no. 89-34 and from seals no. 89-21 and no. 89-30 by the 
appearance of typical cytopathic hanges and by the 
presence of virus particles in negative contrast electron 
microscopy. The three virus isolates were identified as 
PDV-1 by determining their reactivities with a panel of 
morbillivirus-specific monoclonal ntibodies in enzyme- 
linked immunosorbent assays (ELISA) and immuno- 
fluorescence assays (IFA) as shown in Table 13'5'8'9. The 
presence of PDV-1 nucleic acid in RNA extracts from 
these cultures was shown by Southern blot analysis after 
amplification of part of the polymerase-associated (P) 
protein gene of the virus in a polymerase chain reaction 
using a set of PDV-1 specific primers 6'7. No virus could 
be isolated using the same procedure, either from the 
pups in the control group, or from the three other pups 
which displayed mild respiratory symptoms. The develop- 
ment of CDV-specific VN antibodies in the six seal pups 
which displayed respiratory symptoms and in two of the 
five seal pups which remained healthy - one seropositive 
and one seronegative upon admission - are given in 
Figure I. After completion of the vaccination schedule, 
these animals had all developed CDV-specific VN 
antibodies. Seals nos 89-21, 89-27, 89-28, 89-30 and 
89-34 had developed a titre of 30 and seal no. 89-33 a 
titre of 100. After the onset of the disease the antibody 
titres of affected seals nos 89-27, 89-28 and 89-30 
remained the same (titre = 30), whereas those of affected 
seals no. 89-21 and no. 89-33 showed athreefold increase. 
Since in the two non-affected seals (no. 89-26 and no. 
89-29) a threefold increase in titre was also observed, it
could not be concluded whether this titre rise in the 
affected animals was related to the observed infection 
with PDV-1. 
From these and our previous data we conclude that 
vaccination with the candidate CDV-ISCOM vaccine 
does induce CDV-neutralizing antibodies and protection 
against he serious disease known as phocid distemper. 
However, this heterologous vaccination does not induce 
complete protection against replication of PDV-1 in the 
respiratory tract, which may apparently result in mild 
upper respiratory illness. This finding is in agreement 
with results obtained in previously described protection 
experiments u ing other heterologous morbillivirus vac- 
cines. Appel et al. ~° demonstrated that heterologous 
vaccination of dogs with live attenuated measles vaccines 
also induces partial protection against canine distemper. 
Similarly, we have shown that CDV-ISCOMs induce 
complete protection in dogs against CDV infection and 
distemper, whereas measles virus (MV)-ISCOMs only 
induced partial protection against distemper in dogs 1 a. 
To be able to induce complete protection against phocid 
distemper and PDV-1 infection by means of vaccination 
we have considered the development of an homologous 
PDV-I-ISCOM vaccine. If such a vaccine would also 
protect against PDV-1 infection of the respiratory tract, 
this would prevent he threat to non-vaccinated seals 
imposed by temporary spread of PDV-1. It could, 
however, be argued that the incomplete but effective 
protection against phocid distemper afforded by the 
heterologous CDV vaccine is preferable since it would 
still allow subsequent infection with PDV-1, resulting in 
mild upper respiratory disease followed by lifelong 
immunity, similar to the immunity seen after recovery 
from other morbillivirus infections. Contacts with non- 
vaccinated seals should then be prevented until no 
more virus is excreted. 
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